DelveInsight’s “Retinitis Pigmentosa Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in the Retinitis Pigmentosa pipeline landscape. It covers the Retinitis Pigmentosa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinitis Pigmentosa Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Retinitis Pigmentosa Pipeline? Click here to explore the therapies and trials making headlines @ Retinitis Pigmentosa Pipeline Outlook Report

Key Takeaways from the Retinitis Pigmentosa Pipeline Report

• On May 19, 2026, Octant Inc. initiated the phase 1a study will be a single dose, double-masked, placebo-controlled ascending dose escalation (SAD +/- food effect) to evaluate the safety, tolerability, and PK of OCT-980 in healthy volunteers. The phase 1b/2 study will be open-label, multi-center multiple ascending dose escalation (MAD) to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of multiple-ascending doses of OCT-980 for up to 48 weeks, in participants with a genetic diagnosis of Rhodopsin-associated, autosomal dominant Retinitis Pigmentosa (RP).
• On May 15, 2026, SparingVision conducted a Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).
• On May 08, 2026, Janssen Research & Development LLC announced a phase 2 study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
• DelveInsight’s Retinitis Pigmentosa Pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
• The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.
• Promising Retinitis Pigmentosa Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.

Want to know which companies are leading innovation in Retinitis Pigmentosa? Dive into the full pipeline insights @ Retinitis Pigmentosa Clinical Trials Assessment

The Retinitis Pigmentosa Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Retinitis Pigmentosa Pipeline Report also highlights the unmet needs with respect to the Retinitis Pigmentosa.

Retinitis Pigmentosa Overview

Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.

Retinitis Pigmentosa Emerging Drugs Profile

• BIIB-112: Biogen

BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.

• QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.

If you’re tracking ongoing Retinitis Pigmentosa Clinical trials, this press release is a must-read @ Retinitis Pigmentosa Treatment Drugs

The Retinitis Pigmentosa Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
• Retinitis Pigmentosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market.

Retinitis Pigmentosa Companies

Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.

Retinitis Pigmentosa Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Retinitis Pigmentosa Products have been categorized under various Molecule types such as,

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

From emerging drug candidates to competitive intelligence, the Retinitis Pigmentosa Pipeline Report covers it all – check it out now @ Retinitis Pigmentosa Market Drivers and Barriers, and Future Perspectives

Scope of the Retinitis Pigmentosa Pipeline Report

• Coverage- Global
• Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.
• Promising Retinitis Pigmentosa Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.
• Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Retinitis Pigmentosa Treatment landscape in this detailed analysis @ Retinitis Pigmentosa Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BIIB-112: Biogen
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. N-acetylcysteine-amide: Nacuity Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. SPVN 06: SparingVision
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Retinitis Pigmentosa Key Companies
23. Retinitis Pigmentosa Key Products
24. Retinitis Pigmentosa- Unmet Needs
25. Retinitis Pigmentosa- Market Drivers and Barriers
26. Retinitis Pigmentosa- Future Perspectives and Conclusion
27. Retinitis Pigmentosa Analyst Views
28. Retinitis Pigmentosa Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinitis-pigmentosa-retinitis-pipeline-insight